Menu
GeneBe

21-34787885-G-A

Variant summary

Our verdict is Benign. Variant got -14 ACMG points: 0P and 14B. BP4_ModerateBP6_Very_StrongBS2

The NM_001754.5(RUNX1):c.*4250C>T variant causes a 3 prime UTR change. The variant allele was found at a frequency of 0.00104 in 233,312 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.0011 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00095 ( 0 hom. )

Consequence

RUNX1
NM_001754.5 3_prime_UTR

Scores

2

Clinical Significance

Benign reviewed by expert panel B:2

Conservation

PhyloP100: 4.54
Variant links:
Genes affected
RUNX1 (HGNC:10471): (RUNX family transcription factor 1) Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -14 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.26).
BP6
Variant 21-34787885-G-A is Benign according to our data. Variant chr21-34787885-G-A is described in ClinVar as [Benign]. Clinvar id is 339792.Status of the report is reviewed_by_expert_panel, 3 stars.
BS2
High AC in GnomAd at 165 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
RUNX1NM_001754.5 linkuse as main transcriptc.*4250C>T 3_prime_UTR_variant 9/9 ENST00000675419.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
RUNX1ENST00000675419.1 linkuse as main transcriptc.*4250C>T 3_prime_UTR_variant 9/9 NM_001754.5 A1Q01196-8
RUNX1ENST00000300305.7 linkuse as main transcriptc.*4250C>T 3_prime_UTR_variant 8/81 A1Q01196-8
RUNX1ENST00000344691.8 linkuse as main transcriptc.*4250C>T 3_prime_UTR_variant 6/61 P4Q01196-1
RUNX1ENST00000437180.5 linkuse as main transcriptc.*4250C>T 3_prime_UTR_variant 9/95 A1Q01196-8

Frequencies

GnomAD3 genomes
AF:
0.00108
AC:
165
AN:
152224
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000327
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00461
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00151
Gnomad OTH
AF:
0.00
GnomAD4 exome
AF:
0.000951
AC:
77
AN:
80970
Hom.:
0
Cov.:
0
AF XY:
0.00105
AC XY:
39
AN XY:
37216
show subpopulations
Gnomad4 AFR exome
AF:
0.000514
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.0172
Gnomad4 NFE exome
AF:
0.00142
Gnomad4 OTH exome
AF:
0.000444
GnomAD4 genome
AF:
0.00108
AC:
165
AN:
152342
Hom.:
1
Cov.:
32
AF XY:
0.00121
AC XY:
90
AN XY:
74498
show subpopulations
Gnomad4 AFR
AF:
0.000192
Gnomad4 AMR
AF:
0.000327
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00461
Gnomad4 NFE
AF:
0.00151
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.00148
Hom.:
1
Bravo
AF:
0.000691

ClinVar

Significance: Benign
Submissions summary: Benign:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Benign:1
Benign, reviewed by expert panelcurationClinGen Myeloid Malignancy Variant Curation Expert PanelMay 13, 2020The c.*4250C>T variant in the 3' UTR has an MAF of 0.002009 (0.2%, 31/15430 alleles) in the non-Finnish European subpopulation of the gnomAD v2.1.1 cohort and is >= 0.0015 (0.15%) (BA1). This variant is detected in a homozygous state in 1 individual in the gnomAD v2.1.1 population database (BP2). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2. -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Benign:1
Benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 13, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.26
Cadd
Benign
14
Dann
Benign
0.83

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs186103543; hg19: chr21-36160182; API